Target and model assessment
Assess target location, intensity and heterogeneity, then define model-selection criteria.
Application
Antibody, multispecific & TCE studies
Evaluate target expression, effector-cell conditions, dynamic killing and immune activation together in human 3D tumor models.
APPLICATION PATH
Choose the study combination from tumor and immune context
Conventional PDOs support standardized tumor-killing comparisons. When tissue architecture or sample-associated immune context matters, PDO 2.0 / ALI can add that layer alongside mechanism-matched effector cells and functional endpoints.
PDAC PDO 2.0 model and immune context
Design antibody and TCE studies from epithelial identity and T-cell context
PDAC source-tissue/PDO histology, bright-field imaging and CK19/CD3 immunofluorescence establish epithelial and T-cell context; renal PDO 2.0 evidence adds PanCK/CD3 signals across culture time. Candidate studies can then add effector-cell, activation, killing and cytokine assays around the mechanism.
View imagePDAC model identity and tissue context: source-tissue H&E, PDO bright-field and PDO H&E are combined with CK19 and CD3 immunofluorescence to add epithelial and sample-associated T-cell context; measurable components and the assay panel are confirmed during model setup.
TRiCBIO PDAC PDO 2.0 study data
View imageTissue and model context: PanCK, CD3 and DAPI imaging compares tumor-epithelial and CD3-positive immune-cell signals across the source tissue and PDO culture time points.
TRiCBIO ccRCC PDO 2.0 immune-context study dataReview the related model studies
Continue to the PDAC and renal PDO 2.0 studies for model context and immune-assay evidence.
Study focus
What this study can help you decide
- 01How does target expression support model selection?
- 02What target-dependent killing occurs with the selected effectors?
- 03How do activation, killing and cytokine readouts support one another?
Study workflow
How the study moves from question to results
Effector and control design
Define effector source, E:T ratio, preconditioning and target-relevant positive and negative controls.
Killing and immune activation
Combine live or endpoint imaging, viability/apoptosis, activation markers such as CD107a and cytokines.
Candidate comparison
Compare potency, response window and activation profile under consistent conditions to build a clear basis for candidate ranking.
Model options
Match the model to indication, mechanism and sample
We tailor the effector-cell source, E:T ratio and controls to the target and molecular format so killing, activation and cytokine readouts can support candidate comparison together.
PROJECT DISCUSSION
Plan an antibody, multispecific or TCE study
With the target, molecular format, tumor model and effector-cell conditions defined, we can design the relevant killing and activation comparisons.